Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Gilead Sciences stock (GILD)

Buy Gilead Sciences stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Gilead Sciences is a biopharmaceutical company headquartered in California. The company is most well-known as the maker of remdesivir, also known as Veklury, an experimental antiviral drug that may help treat the novel coronavirus.

In May, remdesivir was designated for emergency use authorization for treatment of COVID-19 by the U.S. Food and Drug Administration (FDA), which means it's being used to treat patients in emergency situations. While the drug isn't fully approved by the FDA and its efficacy and long-term effects are still being studied, this designation has generated a lot of buzz for Gilead.

Our top picks for where to buy Gilead Sciences stock

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • Complimentary access to a financial planner and automated investing

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy Gilead Sciences stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – GILD. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Gilead Sciences stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 5 of 5
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a no-advisory-fee robo-advisor and complimentary access to financial planners.
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
eToro
Finder Score: 4 / 5: ★★★★★
EXCLUSIVE
eToro
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.9%
FINDER EXCLUSIVE: Get a guaranteed $15 bonus
No commission stock, ETF and options trades, with 4.9% interest on your options account balance and no options contract fees.
Robinhood
Finder Score: 4.4 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Gilead Sciences stock price (NASDAQ: GILD)

Use our graph to track the performance of GILD stocks over time.

Gilead Sciences shares at a glance

Information last updated 2024-10-05.
Latest market close$85.21
52-week range$60.75 - $85.43
50-day moving average $79.02
200-day moving average $73.78
Wall St. target price$82.49
PE ratio 103.1585
Dividend yield $3.04 (3.64%)
Earnings per share (TTM) $0.82

Is it a good time to buy Gilead Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Gilead Sciences price performance over time

Historical closes compared with the close of $85.21 from 2024-10-08

1 week (2024-10-03) 1.24%
1 month (2024-09-10) 4.63%
3 months (2024-07-10) 23.94%
6 months (2024-04-10) 25.09%
1 year (2023-10-10) 12.16%
2 years (2022-10-10) 32.19%
3 years (2021-10-08) 41.79%
5 years (2019-10-10) 46.04%

Is Gilead Sciences stock undervalued or overvalued?

Valuing Gilead Sciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Gilead Sciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Gilead Sciences's P/E ratio

Gilead Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 103x. In other words, Gilead Sciences shares trade at around 103x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Gilead Sciences's PEG ratio

Gilead Sciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.5031. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Gilead Sciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Gilead Sciences's EBITDA

Gilead Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $13.5 billion.

The EBITDA is a measure of a Gilead Sciences's overall financial performance and is widely used to measure a its profitability.

Gilead Sciences financials

Revenue TTM $27.8 billion
Operating margin TTM 38.72%
Gross profit TTM $21.6 billion
Return on assets TTM 11.55%
Return on equity TTM 5.26%
Profit margin 3.79%
Book value $14.67
Market Capitalization $105.3 billion

TTM: trailing 12 months

Gilead Sciences's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Gilead Sciences.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Gilead Sciences's total ESG risk score

Total ESG risk: 22.15

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Gilead Sciences's overall score of 22.15 (as at 12/31/2018) is pretty good – landing it in it in the 31st percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Gilead Sciences is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Gilead Sciences's environmental score

Environmental score: 0.53/100

Gilead Sciences's environmental score of 0.53 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Gilead Sciences's social score

Social score: 12.97/100

Gilead Sciences's social score of 12.97 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Gilead Sciences's governance score

Governance score: 7.65/100

Gilead Sciences's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Gilead Sciences is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Gilead Sciences's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Gilead Sciences scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Gilead Sciences has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Gilead Sciences Inc was last rated for ESG on: 2019-01-01.

Total ESG score 22.15
Total ESG percentile 30.98
Environmental score 0.53
Environmental score percentile 2
Social score 12.97
Social score percentile 2
Governance score 7.65
Governance score percentile 2
Level of controversy 2

Gilead Sciences share dividends

65%

Dividend payout ratio: 65.11% of net profits

Recently Gilead Sciences has paid out, on average, around 65.11% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.64% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Gilead Sciences shareholders could enjoy a 3.64% return on their shares, in the form of dividend payments. In Gilead Sciences's case, that would currently equate to about $3.04 per share.

Gilead Sciences's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Gilead Sciences's most recent dividend payout was on 26 September 2024. The latest dividend was paid out to all shareholders who bought their shares by 12 September 2024 (the "ex-dividend date").

Have Gilead Sciences's shares ever split?

Gilead Sciences's shares were split on a 2:1 basis on 27 January 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Gilead Sciences shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Gilead Sciences shares which in turn could have impacted Gilead Sciences's share price.

Gilead Sciences share price volatility

Over the last 12 months, Gilead Sciences's shares have ranged in value from as little as $60.7503 up to $85.43. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gilead Sciences's is 0.199. This would suggest that Gilead Sciences's shares are less volatile than average (for this exchange).

Gilead Sciences overview

Gilead Sciences, Inc. , a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc. ; Merck Sharp & Dohme Corp. ; Pionyr Immunotherapeutics Inc.

Frequently asked questions

null
What percentage of Gilead Sciences is owned by insiders or institutions?
Currently 0.119% of Gilead Sciences shares are held by insiders and 87.774% by institutions.
How many people work for Gilead Sciences?
Latest data suggests 18,000 work at Gilead Sciences.
When does the fiscal year end for Gilead Sciences?
Gilead Sciences's fiscal year ends in December.
Where is Gilead Sciences based?
Gilead Sciences's address is: 333 Lakeside Drive, Foster City, CA, United States, 94404
What is Gilead Sciences's ISIN number?
Gilead Sciences's international securities identification number is: US3755581036
What is Gilead Sciences's CUSIP number?
Gilead Sciences's Committee on Uniform Securities Identification Procedures number is: 375558103

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site